STOCK TITAN

Vanguard disaggregates holdings after realignment — Harmony Biosciences (HRMY)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Harmony Biosciences Holdings Inc: an amendment to a Schedule 13G/A reports that The Vanguard Group holds 0 shares of common stock, representing 0 % of the class. The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report beneficial ownership separately.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; reported zero beneficial ownership.

The Vanguard Group submits an amendment showing 0 shares and 0 % ownership. The cover text cites an internal realignment on January 12, 2026 and reliance on SEC Release No. 34-39538 for disaggregated reporting.

Timing and cash-flow treatment are not described in the excerpt; subsequent filings from the reporting subsidiaries will carry their respective ownership details.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Who filed the Schedule 13G/A for HRMY?

The filing was submitted by The Vanguard Group. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026, and lists Vanguard's Malvern, PA address.

How many Harmony Biosciences (HRMY) shares does Vanguard report owning?

The Vanguard Group reports owning 0 shares of Harmony Biosciences common stock, representing 0 % of the class, as stated in the amendment's ownership section.

Why does Vanguard report zero ownership in this amendment?

The amendment explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Does the filing identify any person with more than 5% ownership?

The amendment states that no other person's interest in the securities reported herein is more than 5 %, and lists the filing as an ownership report of five percent or less.

Who signed the Schedule 13G/A amendment for Vanguard?

The amendment is signed by Ashley Grim, with title Head of Global Fund Administration, and dated 03/27/2026, certifying the disclosure in the submission.
Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

View HRMY Stock Overview

HRMY Rankings

HRMY Latest News

HRMY Latest SEC Filings

HRMY Stock Data

1.59B
50.25M
Biotechnology
Pharmaceutical Preparations
Link
United States
PLYMOUTH MEETING